Blog

The Need for Greater Awareness for Premenstrual Disorders

Picture above: Dr Orla Conlon, Consultant Gynaecologist, Senator Patricia Stephenson, Shauna Halpin PMDD advocate, Dr Yvonne Hartnett, Aspire Fellow Women’s Mental Health, Samantha Trevaskis, PMDD Researcher at Leinster House 4th March 2026.

April is Premenstrual Dysphoric Disorder (PMDD) Awareness month. Dr Yvonne Hartnett, psychiatrist and Aspire Fellow in Women’s Mental Health at St Vincent’s University Hospital, has written a piece to shed light on a condition that is underdiagnosed.

PMDD is a mood disorder that affects about 1 in 20 people with a menstrual cycle (3-7% of women of reproductive age)1. It was moved from the appendix to the main body of the DSM in 2013 and has been included in ICD-11 since 2019. PMDD is a distinct diagnosis from major depression in that symptoms are confined to the phase of the menstrual cycle between ovulation and menses (the luteal phase), with resolution of symptoms between menses and ovulation (the follicular phase).

Typical symptoms include irritability, mood swings, low mood, anxiety, and poor concentration. Symptoms are the result of an abnormal brain reaction to normal fluctuating ovarian hormones, meaning it is a disorder of the brain, not an endocrinological or gynaecological disorder2. There are no hormone level abnormalities that would distinguish those with and without the condition; therefore, blood tests will not reveal the diagnosis.

Symptoms are dependent on ovulation and disappear during pregnancy and after menopause but can worsen in the preceding perimenopausal years. Currently available evidence implicates a derivative of progesterone, a neurosteroid called allopregnanolone, and its effect on the GABAergic system3, but there is emerging evidence of an inflammatory pathophysiology. Additionally, a history of trauma appears to predispose to this diagnosis4.

Given the overlap in symptoms with other conditions, it is often misdiagnosed in psychiatric practice if the temporal relationship with the menstrual cycle is not appreciated by the patient or clinician. One in four people with PMDD are misdiagnosed with bipolar disorder5. It can also be misdiagnosed as emotionally unstable personality disorder (EUPD), anxiety, or depression. Premenstrual exacerbation of an underlying condition (PME) is a common phenomenon that occurs in depressive disorders, anxiety disorders, EUPD, ADHD, and psychosis6.

The association between premenstrual disorders and suicidality is of critical importance. Among those with PMDD, 72% have experienced active suicidal ideation, one-third have attempted suicide, and over half have self-harmed at some point in their life7. Given the poor predictive value of suicide risk assessment, recognising cyclicity in suicidality in this subset of women offers a potential target for suicide prevention strategies.

Qualitative research consistently demonstrates lengthy diagnostic delays, ineffective treatments, and unsatisfactory interactions with clinicians8. A lack of awareness among healthcare professionals, including psychiatrists, is ostensibly a common experience for those ultimately diagnosed. Premenstrual disorders have a profound impact on quality of life, comparable to that of major depression9. Recurring symptoms rob women of one to two weeks of every menstrual cycle during a time when relationships, families, and careers are usually built.

Treatment strategies fall into two categories: modifying the effect of reproductive hormone fluctuations on the brain or eliminating these fluctuations10. Depending on patient preference, first-line treatment can be either an SSRI (taken continuously or during the luteal phase only) or a combined oral contraceptive pill (taken without breaks to maintain steady hormone levels). If these strategies are not effective, eliminating the menstrual cycle completely through chemical or surgical menopause are 3rd and 4th line treatments respectively. This means that treatment for one individual might take a disjointed path through general practice, psychiatry, and gynaecology, with no established clinical pathways to provide for integrated care.

In the UK, the recognition of PMDD is growing. A plenary session on this topic was well attended at the Royal College of Psychiatrists Congress in June 2025. While the National Association for Premenstrual Syndromes (NAPS) was founded in 1984, the International Association for Premenstrual Disorders (IAPMD) UK was launched in recent months and is due to hold its first conference in August 2026. I was recently invited, along with other experts and those with lived experience, to speak at a briefing session in Leinster House on PMDD. It was evident from this that the current healthcare landscape presents significant challenges to timely diagnosis and intervention. There is a need for increased awareness among both the general public and healthcare professionals to alleviate the suffering associated with this condition.

 

Clinical recommendations

  1. Sensitive exploration of menstrual history should be included in the clinical histories of all female premenopausal patients, particularly those experiencing suicidal thoughts. As retrospective recall is unreliable, women and girls attending mental health professionals should be encouraged to track their symptoms across two menstrual cycles to ascertain any association with their cycle. Given that PMDD can be particularly severe in the years following menarche, this consideration is especially crucial for CAMHS.
  2. The International Association for Premenstrual Disorders (IAPMD) provides evidence-based, high quality clinical information for both professionals and the general public, supports PMDD research and organises online support groups for those affected. IAPMD.org

 

Further Reading

Premenstrual Dysphoric Disorder: Current barriers to diagnosis and treatment

https://publicpolicy.ie/papers/policy-brief/premenstrual-dysphoric-disorder-current-barriers-to-diagnosis-and-treatment/

Samantha Trevaskis, University College Dublin, and Dr Yvonne Hartnett , University College Dublin & St Vincent’s University Hospital

 

References

  1. Reilly TJ, Patel S, Unachukwu IC, et al. The prevalence of premenstrual dysphoric disorder: Systematic review and meta-analysis. J Affect Disord 2024;349:534-40. doi: 10.1016/j.jad.2024.01.066
  2. Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. Am J Psychiatry 2017;174(10):980-89. doi: 10.1176/appi.ajp.2017.16101113 [published Online First: 20170421]
  3. Schweizer-Schubert S, Gordon JL, Eisenlohr-Moul TA, et al. Steroid Hormone Sensitivity in Reproductive Mood Disorders: On the Role of the GABA(A) Receptor Complex and Stress During Hormonal Transitions. Front Med (Lausanne) 2020;7:479646. doi: 10.3389/fmed.2020.479646 [published Online First: 20210118]
  4. Grewal JK, Mu E, Li Q, et al. The prevalence of traumatic exposure in women with premenstrual dysphoric disorder (PMDD): a systematic review. Arch Women’s Ment Heal 2025;28(4):723-40. doi: 10.1007/s00737-024-01536-z
  5. IAPMD. IAPMD Global Survey. https://iapmd.org/facts-and-figures: IAPMD, 2023.
  6. Nolan LN, Hughes L. Premenstrual exacerbation of mental health disorders: a systematic review of prospective studies. Arch Womens Ment Health 2022;25(5):831-52. doi: 10.1007/s00737-022-01246-4 [published Online First: 20220722]
  7. Eisenlohr-Moul T, Divine M, Schmalenberger K, et al. Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry 2022;22(1):199. doi: 10.1186/s12888-022-03851-0 [published Online First: 20220319]
  8. Funnell EL, Martin-Key NA, Spadaro B, et al. Help-seeking behaviours and experiences for mental health symptoms related to the menstrual cycle: a UK-wide exploratory survey. npj Women’s Health 2024;2(1):2. doi: 10.1038/s44294-023-00004-w
  9. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003;28 Suppl 3:1-23. doi: 10.1016/s0306-4530(03)00098-2
  10. Nevatte T, O’Brien PM, Backstrom T, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health 2013;16(4):279-91. doi: 10.1007/s00737-013-0346-y [published Online First: 20130427]